Loading clinical trials...
Loading clinical trials...
Rituximab is the first drug approved by the United States Food and Drug Administration (FDA) for the treatment of patients with granulomatosis with polyangiitis (Wegener's granulomatosis) or microscop...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Johns Hopkins University
Collaborators
NCT06940661 · Granulomatosis With Polyangiitis
NCT06983821 · Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA)
NCT02593565 · Vasculitis, Behcet's Disease, and more
NCT01241305 · Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, and more
NCT03004326 · Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis, and more
University of Alabama
Birmingham, Alabama
Johns Hopkins University
Baltimore, Maryland
Boston University
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions